Advances of gene therapy for primary immunodeficiencies

F1000Research

Volumn 5, Issue , 2016, Pages

  Candotti, Fabio ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; MELPHALAN; RETROVIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; CCND2 GENE; CHRONIC GRANULOMATOUS DISEASE; CRISPR CAS SYSTEM; CRYOPRESERVATION; ENZYME REPLACEMENT; EVI1 GENE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; LEUKEMOGENESIS; LMO2 GENE; MDS1 GENE; MN1 GENE; NONHUMAN; NONMYELOABLATIVE CONDITIONING; ONCOGENE; PHENOTYPE; PLURIPOTENT STEM CELL; PRDM16 GENE; REVIEW; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

EID: 84964671802     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.7512.1     Document Type: Review

References (107)

1. Picard C Al-Herz W Bousfiha A: Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015.35(8):696-726. 26482257 10.1007/s10875-015-0201-1 4659841
2. Gennery AR Slatter MA Grandin L: Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602-10.e1-11. 20673987 10.1016/j.jaci.2010.06.015
3. Miller AD: Retroviral vectors. Curr Top Microbiol Immunol. 1992;158:1-24. 1582242
4. Blaese RM Culver KW Miller AD: T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science. 1995;270(5235):475-80. 7570001 10.1126/science.270.5235.475
5. Bordignon C Notarangelo LD Nobili N: Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science. 1995;270(5235):470-5. 7570000 10.1126/science.270.5235.470
6. Kohn DB Weinberg KI Nolta JA: Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med. 1995;1(10):1017-23. 7489356 10.1038/nm1095-1017 3013367
7. Hoogerbrugge PM van Beusechem VW Fischer A: Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 1996;3(2):179-83. 8867866
8. Kiem HP Andrews RG Morris J: Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood. 1998;92(6):1878-86. 9731044
9. Tisdale JF Hanazono Y Sellers SE: Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood. 1998;92(4):1131-41. 9694700
10. Cavazzana-Calvo M Hacein-Bey S de Saint Basile G: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-72. 10784449 10.1126/science.288.5466.669
11. Aiuti A Slavin S Aker M: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296(5577):2410-3. 12089448 10.1126/science.1070104 F1000 Recommendation
12. Gaspar HB Parsley KL Howe S: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364(9452):2181-7. 15610804 10.1016/S0140-6736(04)17590-9
13. Boztug K Schmidt M Schwarzer A: Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med. 2010;363(20):1918-27. 21067383 10.1056/NEJMoa1003548 3064520 F1000 Recommendation
14. Hacein-Bey-Abina S Garrigue A Wang GP: Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132-42. 18688285 10.1172/JCI35700 2496963 F1000 Recommendation
15. Howe SJ Mansour MR Schwarzwaelder K: Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9):3143-50. 18688286 10.1172/JCI35798 2496964
16. Braun CJ Boztug K Paruzynski A: Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med. 2014;6(227):227ra33. 24622513 10.1126/scitranslmed.3007280 F1000 Recommendation
17. Noguchi M Yi H Rosenblatt HM: Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993;73(1):147-57. 8462096 10.1016/0092-8674(93)90167-O
18. Puck JM Deschênes SM Porter JC: The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet. 1993;2(8):1099-104. 8401490 10.1093/hmg/2.8.1099
19. Thornhill SI Schambach A Howe SJ: Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther. 2008;16(3):590-8. 18180772 10.1038/sj.mt.6300393
20. Hacein-Bey-Abina S Pai SY Gaspar HB: A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med. 2014;371(15):1407-17. 25295500 10.1056/NEJMoa1404588 4274995 F1000 Recommendation
21. Wu X Li Y Crise B: Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300(5626):1749-51. 12805549 10.1126/science.1083413 F1000 Recommendation
22. Zhou S Mody D DeRavin SS: A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood. 2010;116(6):900-8. 20457870 10.1182/blood-2009-10-250209 2924228 F1000 Recommendation
23. De Ravin SS Wu X Theobald N: Lentiviral Hematopoietic Stem Cell Gene Therapy for Older Patients with X-Linked Severe Combined Immunodeficiency. Blood. 2015;126(23):261-261. Reference Source
24. Bosticardo M Marangoni F Aiuti A: Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood. 2009;113(25):6288-95. 19351959 10.1182/blood-2008-12-115253
25. Moratto D Giliani S Bonfim C: Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood. 2011;118(6):1675-84. 21659547 10.1182/blood-2010-11-319376 3156052
26. Dupré L Trifari S Follenzi A: Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther. 2004;10(5):903-15. 15509508 10.1016/j.ymthe.2004.08.008 F1000 Recommendation
27. Aiuti A Biasco L Scaramuzza S: Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341(6148):1233151. 23845947 10.1126/science.1233151 4375961 F1000 Recommendation
28. Hacein-Bey Abina S Gaspar HB Blondeau J: Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA. 2015;313(15):1550-63. 25898053 10.1001/jama.2015.3253 F1000 Recommendation
29. Chu JI Henderson LA Armant M: Gene Therapy Using a Self-Inactivating Lentiviral Vector Improves Clinical and Laboratory Manifestations of Wiskott-Aldrich Syndrome. Blood. 2015;126:260-260. Reference Source
30. Kang EM Marciano BE DeRavin S: Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2011;127(6):1319-26; quiz 1327-8. 21497887 10.1016/j.jaci.2011.03.028 3133927
31. Malech HL Sekhsaria S Whiting Theobald N: Prolonged detection of oxidase-positive neutrophils in the peripheral blood of five patients following a single cycle of gene therapy for chronic granulomatous disease. Blood. 1996;88((abstr. suppl. 1)):486a.
32. Malech HL Horwitz ME Linton GF: Extended production of oxidase normal neutrophils in X-linked chronic granulomatous disease (CGD) following gene therapy with gp91(phox) transduced CD34 + cells. Blood. 1998;92:690A.
33. Goebel WS Dinauer MC: Gene therapy for chronic granulomatous disease. Acta Haematol. 2003;110(2-3):86-92. 14583668 10.1159/000072457
34. Kang EM Choi U Theobald N: Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood. 2010;115(4):783-91. 19965657 10.1182/blood-2009-05-222760 2815517
35. Grez M Reichenbach J Schwäble J: Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther. 2011;19(1):28-35. 21045810 10.1038/mt.2010.232 3017455
36. Ott MG Schmidt M Schwarzwaelder K: Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401-9. 16582916 10.1038/nm1393 F1000 Recommendation
37. Stein S Ott MG Schultze-Strasser S: Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16(2):198-204. 20098431 10.1038/nm.2088
38. Aiuti A Bacchetta R Seger R: Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol. 2012;24(5):585-91. 22909900 10.1016/j.coi.2012.07.012
39. Bianchi M Hakkim A Brinkmann V: Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood. 2009;114(13):2619-22. 19541821 10.1182/blood-2009-05-221606 2756123 F1000 Recommendation
40. Siler U Paruzynski A Holtgreve-Grez H: Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing. Curr Gene Ther. 2015;15(4):416-27. 25981636 10.2174/1566523215666150515145255 F1000 Recommendation
41. Moreno-Carranza B Gentsch M Stein S: Transgene optimization significantly improves SIN vector titers, gp91 phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther. 2009;16(1):111-8. 18784749 10.1038/gt.2008.143 F1000 Recommendation
42. Santilli G Almarza E Brendel C: Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther. 2011;19(1):122-32. 20978475 10.1038/mt.2010.226 3017453 F1000 Recommendation
43. Güngör T Teira P Slatter M: Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436-48. 24161820 10.1016/S0140-6736(13)62069-3
44. Chiriaco M Farinelli G Capo V: Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. Mol Ther. 2014;22(8):1472-83. 24869932 10.1038/mt.2014.87 4435596
45. Hirschhorn R Grunebaum E Roifman C: Immunodeficiency Due to Defects of Purine Metabolism: Territorial Administration under Attack in Orleans and Washington. In: Hans D. Ochs, MD, Dr.med, C. I. Edvard Smith, PhD, Jennifer M. Puck, MD, editors. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach.Oxford University Press,2013;188-230. 10.1093/med/9780195389838.003.0014
46. Gaspar HB Aiuti A Porta F: How I treat ADA deficiency. Blood. 2009;114(17):3524-32. 19638621 10.1182/blood-2009-06-189209 2766674
47. Hassan A Booth C Brightwell A: Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615-24; quiz 3626. 22791287 10.1182/blood-2011-12-396879
48. Onodera M Ariga T Kawamura N: Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood. 1998;91(1):30-6. 9414266
49. Misaki Y Ezaki I Ariga T: Gene-transferred oligoclonal T cells predominantly persist in peripheral blood from an adenosine deaminase-deficient patient during gene therapy. Mol Ther. 2001;3(1):24-7. 11162307 10.1006/mthe.2000.0232
50. Aiuti A Vai S Mortellaro A: Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002;8(5):423-5. 11984564 10.1038/nm0502-423
51. Muul LM Tuschong LM Soenen SL: Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood. 2003;101(7):2563-9. 12456496 10.1182/blood-2002-09-2800
52. Otsu M: Update on a Japanese clinical trial of stem cell gene therapy for ADA-deficiency. Human Gene Therapy. 2010;21(10):1437-1437.
53. Aiuti A Cattaneo F Galimberti S: Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447-58. 19179314 10.1056/NEJMoa0805817 F1000 Recommendation
54. Gaspar HB Bjorkegren E Parsley K: Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther. 2006;14(4):505-13. 16905365 10.1016/j.ymthe.2006.06.007 F1000 Recommendation
55. Gaspar HB Cooray S Gilmour KC: Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011;3(97):97ra80. 21865538 F1000 Recommendation
56. Candotti F Shaw KL Muul L: Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012;120(18):3635-46. 22968453 10.1182/blood-2012-02-400937 3488882
57. Carbonaro DA Zhang L Jin X: Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther. 2014;22(3):607-22. 24256635 10.1038/mt.2013.265 3944341 F1000 Recommendation
58. Gaspar B Buckland K Rivat C: Immunological and Metabolic Correction After Lentiviral Vector Mediated Haematopoietic Stem Cell Gene Therapy for ADA Deficiency. Journal of Clinical Immunology. 2014;34:S167-S168.
59. Pike-Overzet K Rodijk M Ng YY: Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer. Leukemia. 2011;25(9):1471-83. 21617701 10.1038/leu.2011.106 F1000 Recommendation
60. van Til NP de Boer H Mashamba N: Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. Mol Ther. 2012;20(10):1968-80. 22692499 10.1038/mt.2012.110 3464632 F1000 Recommendation
61. van Til NP Sarwari R Visser TP: Recombination-activating gene 1 ( Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome. J Allergy Clin Immunol. 2014;133(4):1116-23. 24332219 10.1016/j.jaci.2013.10.009 F1000 Recommendation
62. Pike-Overzet K Baum C Bredius RG: Successful RAG1-SCID gene therapy depends on the level of RAG1 expression. J Allergy Clin Immunol. 2014;134(1):242-3. 25117803 10.1016/j.jaci.2014.04.033
63. Mostoslavsky G Fabian AJ Rooney S: Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci U S A. 2006;103(44):16406-11. 17062750 10.1073/pnas.0608130103 1637595 F1000 Recommendation
64. Benjelloun F Garrigue A Demerens-de Chappedelaine C: Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells. Mol Ther. 2008;16(8):1490-9. 18560421 10.1038/mt.2008.118 F1000 Recommendation
65. Lagresle-Peyrou C Benjelloun F Hue C: Restoration of human B-cell differentiation into NOD-SCID mice engrafted with gene-corrected CD34 + cells isolated from Artemis or RAG1-deficient patients. Mol Ther. 2008;16(2):396-403. 18223550 10.1038/sj.mt.6300353 F1000 Recommendation
66. Nelson DM Butters KA Markert ML: Correction of proliferative responses in purine nucleoside phosphorylase (PNP)-deficient T lymphocytes by retroviral-mediated PNP gene transfer and expression. J Immunol. 1995;154(6):3006-14. 7876563
67. Bauer TR Hickstein DD: Gene therapy for leukocyte adhesion deficiency. Curr Opin Mol Ther. 2000;2(4):383-8. 11249768
68. Sorrentino BP Lu T Ihle J: A clinical attempt to treat JAK3-deficient SCID using retroviral-mediated gene transfer to bone marrow CD34 + cells. Molecular Therapy. 2003;7:S449. Reference Source
69. Urnov FD Miller JC Lee Y: Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005;435(7042):646-51. 15806097 10.1038/nature03556 F1000 Recommendation
70. Genovese P Schiroli G Escobar G: Targeted genome editing in human repopulating haematopoietic stem cells. Nature. 2014;510(7504):235-40. 24870228 10.1038/nature13420 4082311 F1000 Recommendation
71. Zou J Sweeney CL Chou BK: Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood. 2011;117(21):5561-72. 21411759 10.1182/blood-2010-12-328161 3110021 F1000 Recommendation
72. Willis RC Jolly DJ Miller AD: Partial phenotypic correction of human Lesch-Nyhan (hypoxanthine-guanine phosphoribosyltransferase-deficient) lymphoblasts with a transmissible retroviral vector. J Biol Chem. 1984;259(12):7842-9. 6203897
73. Kantoff PW Kohn DB Mitsuya H: Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A. 1986;83(17):6563-7. 3489233 10.1073/pnas.83.17.6563 386544
74. Sun JY Pacheco-Castro A Borroto A: Construction of retroviral vectors carrying human CD3 gamma cDNA and reconstitution of CD3 gamma expression and T cell receptor surface expression and function in a CD3 gamma-deficient mutant T cell line. Hum Gene Ther. 1997;8(9):1041-8. 9189762 10.1089/hum.1997.8.9-1041
75. Candotti F Oakes SA Johnston JA: In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J Exp Med. 1996;183(6):2687-92. 8676091 10.1084/jem.183.6.2687 2192605
76. Oakes SA Candotti F Johnston JA: Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity. 1996;5(6):605-15. 8986719 10.1016/S1074-7613(00)80274-5
77. Bunting KD Sangster MY Ihle JN: Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med. 1998;4(1):58-64. 9427607 10.1038/nm0198-058
78. Bunting KD Flynn KJ Riberdy JM: Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency. Proc Natl Acad Sci U S A. 1999;96(1):232-7. 9874801 10.1073/pnas.96.1.232 15122
79. Bunting KD Lu T Kelly PF: Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation. Hum Gene Ther. 2000;11(17):2353-64. 11096440 10.1089/104303400750038462
80. Lagresle-Peyrou C Yates F Malassis-Séris M: Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity. Blood. 2006;107(1):63-72. 16174758 10.1182/blood-2005-05-2032
81. Yates F Malassis-Séris M Stockholm D: Gene therapy of RAG-2-/- mice: sustained correction of the immunodeficiency. Blood. 2002;100(12):3942-9. 12393742 10.1182/blood-2002-03-0782
82. Lagresle-Peyrou C Six EM Picard C: Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nat Genet. 2009;41(1):106-11. 19043416 10.1038/ng.278 2612090 F1000 Recommendation
83. Liao P Toro A Min W: Lentivirus gene therapy for purine nucleoside phosphorylase deficiency. J Gene Med. 2008;10(12):1282-93. 18924118 10.1002/jgm.1261
84. Taylor N Bacon KB Smith S: Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene. J Exp Med. 1996;184(5):2031-6. 8920891 10.1084/jem.184.5.2031 2192882
85. Steinberg M Swainson L Schwarz K: Retrovirus-mediated transduction of primary ZAP-70-deficient human T cells results in the selective growth advantage of gene-corrected cells: implications for gene therapy. Gene Ther. 2000;7(16):1392-400. 10981666 10.1038/sj.gt.3301249
86. Otsu M Steinberg M Ferrand C: Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells. Blood. 2002;100(4):1248-56. 12149205 10.1182/blood-2002-01-0247
87. Adjali O Marodon G Steinberg M: In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer. J Clin Invest. 2005;115(8):2287-95. 16075064 10.1172/JCI23966 1180533
88. Irla M Saade M Kissenpfennig A: ZAP-70 restoration in mice by in vivo thymic electroporation. PLoS One. 2008;3(4):e2059. 18446234 10.1371/journal.pone.0002059 2323614
89. Bradley MB Fernandez JM Ungers G: Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA. J Immunol. 1997;159(3):1086-95. 9233601
90. Yu PW Tabuchi RS Kato RM: Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer. Blood. 2004;104(5):1281-90. 15142874 10.1182/blood-2003-09-3044
91. Moreau T Barlogis V Bardin F: Development of an enhanced B-specific lentiviral vector expressing BTK: a tool for gene therapy of XLA. Gene Ther. 2008;15(12):942-52. 18323795 10.1038/gt.2008.17
92. Kerns HM Ryu BY Stirling BV: B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia. Blood. 2010;115(11):2146-55. 20093406 10.1182/blood-2009-09-241869 2844021
93. Ng YY Baert MR Pike-Overzet K: Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK. Leukemia. 2010;24(9):1617-30. 20574453 10.1038/leu.2010.140
94. Brown MP Topham DJ Sangster MY: Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med. 1998;4(11):1253-60. 9809548 10.1038/3233
95. Tahara M Pergolizzi RG Kobayashi H: Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat Med. 2004;10(8):835-41. 15273748 10.1038/nm1086
96. Romero Z Torres S Cobo M: A tissue-specific, activation-inducible, lentiviral vector regulated by human CD40L proximal promoter sequences. Gene Ther. 2011;18(4):364-71. 21107438 10.1038/gt.2010.144
97. Carmo M Risma KA Arumugam P: Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency. Mol Ther. 2015;23(4):737-45. 25523759 10.1038/mt.2014.242 4395774
98. Rivat C Booth C Alonso-Ferrero M: SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease. Blood. 2013;121(7):1073-6. 23223356 10.1182/blood-2012-07-445858 3779401
99. Wilson JM Ping AJ Krauss JC: Correction of CD18-deficient lymphocytes by retrovirus-mediated gene transfer. Science. 1990;248(4961):1413-6. 1972597 10.1126/science.1972597
100. Bauer TR Jr Miller AD Hickstein DD: Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines by using retroviral vectors having a gibbon ape leukemia virus envelope. Blood. 1995;86(6):2379-87. 7662985
101. Bauer TR Schwartz BR Liles WC: Retroviral-mediated gene transfer of the leukocyte integrin CD18 into peripheral blood CD34 + cells derived from a patient with leukocyte adhesion deficiency type 1. Blood. 1998;91(5):1520-6. 9473215
102. Yorifuji T Wilson RW Beaudet AL: Retroviral mediated expression of CD18 in normal and deficient human bone marrow progenitor cells. Hum Mol Genet. 1993;2(9):1443-8. 7902162 10.1093/hmg/2.9.1443
103. Bauer TR Jr Hai M Tuschong LM: Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. Blood. 2006;108(10):3313-20. 16868255 10.1182/blood-2006-03-006908 1895427
104. Bauer TR Jr Allen JM Hai M: Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med. 2008;14(1):93-7. 18157138 10.1038/nm1695 4675671
105. Nelson EJ Tuschong LM Hunter MJ: Lentiviral vectors incorporating a human elongation factor 1alpha promoter for the treatment of canine leukocyte adhesion deficiency. Gene Ther. 2010;17(5):672-7. 20164857 10.1038/gt.2010.7 3461956
106. Hunter MJ Tuschong LM Fowler CJ: Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression. Mol Ther. 2011;19(1):113-21. 20859258 10.1038/mt.2010.203 3017439
107. Hunter MJ Zhao H Tuschong LM: Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters. Hum Gene Ther. 2011;22(6):689-96. 21275758 10.1089/hum.2010.130 3107578